Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Becton Dickinson (BDX)

BD quarterly revenue rose to $4.5 billion; adjusted EPS fell to $2.50 from $2.78

Mixed Impact 3 of 5 earnings Written later

BD furnished recast historical financials, with its former Biosciences and Diagnostic Solutions business shown as discontinued operations following its February 9, 2026 combination with Waters Corporation. For the quarter ended December 31, 2025, revenue rose to $4,486 million from $4,333 million, and GAAP diluted EPS was $1.34 versus $1.04, but adjusted diluted EPS from continuing operations fell to $2.50 from $2.78.

Key points

  • Revenue for the three months ended December 31, 2025 was $4,486 million, up from $4,333 million a year earlier.
  • GAAP diluted EPS was $1.34, compared with $1.04; diluted EPS from continuing operations was $1.09, compared with $0.50.
  • Adjusted diluted EPS from continuing operations was $2.50, down from $2.78; adjusted operating income was $978 million versus $1,005 million.

The filing

CompanyBecton Dickinson (BDX)
Form8-K, current report
Filed with the SECApr 2, 2026, 4:18 PM ET
Accession number0001628280-26-023185

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.